[en] [en] BACKGROUND: Tralokinumab, the first fully human monoclonal antibody that binds specifically to interleukin-13, was safe and effective for treating atopic dermatitis (AD) in clinical trials, but real-life experience is still limited.
OBJECTIVES: The objective of this study was to evaluate the effectiveness and safety of tralokinumab in severe AD in a real-life multicenter prospective cohort.
METHODS: Adult patients with severe AD were enrolled between January 2022 and July 2022 and received tralokinumab subcutaneously for 16 weeks. Objective and subjective scores were collected at baseline, weeks 6 and 16. Adverse events were reported throughout the study.
RESULTS: Twenty-one patients were included. An improvement of at least 75% on the Eczema Area and Severity Index (EASI 75) was achieved in 66.7% of patients at week 16. The median objective and subjective scores at week 16 were significantly (p < 0.001) lower than those at baseline. Combination with cyclosporine was sometimes necessary at the beginning of treatment, and addition of upadacitinib was required for some patients with very severe disease during the treatment. The most frequent adverse events were flares of eczema (23.8%) and reactions at injection site (19.0%). No cases of conjunctivitis were reported. Four patients (19.0%) discontinued treatment.
CONCLUSIONS: Tralokinumab is an effective first-line biotherapy for severe AD. However, therapeutic response may be progressive. Safety data were reassuring. Atopic dermatitis flares or reactions at the injection site may lead to discontinuation of treatment. A history of conjunctivitis on dupilumab is not a contraindication to the initiation of tralokinumab.
Disciplines :
Dermatology
Author, co-author :
De Greef, Axel ; Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium. axel.degreef@saintluc.uclouvain.be
Ghislain, Pierre-Dominique; Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium
Bulinckx, Audrey; Department of Dermatology, Grand Hôpital de Charleroi, Charleroi, Belgium
Coster, Alison; Department of Dermatology, CHU UCL Namur Sainte-Elisabeth, Namur, Belgium
de Halleux, Céline; Department of Dermatology, Clinique Saint-Jean, Brussels, Belgium
Damsin, Thomas ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie
Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769–79. 10.1016/j.jaci.2014.08.008. DOI: 10.1016/j.jaci.2014.08.008
Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160. 10.2340/00015555-3510. DOI: 10.2340/00015555-3510
Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144–51. 10.1016/j.anai.2019.04.020. DOI: 10.1016/j.anai.2019.04.020
Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–93. 10.1111/all.1340. DOI: 10.1111/all.1340
Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2. 10.1016/j.anai.2020.12.020. DOI: 10.1016/j.anai.2020.12.020
Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC. New and emerging systemic treatments for atopic dermatitis. Drugs. 2020;80(11):1041–52. 10.1007/s40265-020-01335-7. DOI: 10.1007/s40265-020-01335-7
Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. 10.1111/all.13954. DOI: 10.1111/all.13954
Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–49. 10.1111/bjd.19574. DOI: 10.1111/bjd.19574
Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450–63. 10.1111/bjd.19573. DOI: 10.1111/bjd.19573
Gutermuth J, Pink AE, Worm M, Soldbro L, BjerregårdØland C, Weidinger S. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022;186(3):440–52. 10.1111/bjd.20832. DOI: 10.1111/bjd.20832
Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines.” J Am Acad Dermatol. 2005;52(1):156. 10.1016/j.jaad.2003.08.003. DOI: 10.1016/j.jaad.2003.08.003
Blauvelt A, Langley RG, Lacour JP, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815–24. 10.1016/j.jaad.2022.07.019. DOI: 10.1016/j.jaad.2022.07.019
Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143–51. 10.1016/j.jaad.2019.02.053. DOI: 10.1016/j.jaad.2019.02.053
Jang DH, Heo SJ, Jung HJ, Park MY, Seo SJ, Ahn J. Retrospective study of dupilumab treatment for moderate to severe atopic dermatitis in Korea: efficacy and safety of dupilumab in real-world practice. J Clin Med. 2020;9(6):1982. 10.3390/jcm9061982. DOI: 10.3390/jcm9061982
Matstutani M, Imai Y, Inoue Y, et al. Real-world use of dupilumab for 53 patients with atopic dermatitis in Japan. J Cutan Immunol Allergy. 2020;3:35–6. 10.1002/cia2.12099. DOI: 10.1002/cia2.12099
Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022;158(5):523–32. 10.1001/jamadermatol.2022.0455. DOI: 10.1001/jamadermatol.2022.0455
Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, Dellavalle R, Chaiyakunapruk N. Systemic treatments for eczema: a network meta-analysis. Cochrane Database Syst Rev. 2020;9(9): CD013206. 10.1002/14651858.CD013206.pub2. DOI: 10.1002/14651858.CD013206.pub2
Simpson EL, Merola JF, Silverberg JI, et al. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials [published online ahead of print, 2022 Sep 9]. Br J Dermatol. 2022. 10.1111/bjd.21867. DOI: 10.1111/bjd.21867
Neagu N, Dianzani C, Avallone G, et al. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review. J Eur Acad Dermatol Venereol. 2022;36(6):820–35. 10.1111/jdv.17981. DOI: 10.1111/jdv.17981
